Vaxxas has in-licensed UT Austin’s HexaPro vaccine, as well as a companion background technology the company is licensing from the NIH. Vaxxas says the licenses—whose values have not been disclosed—will enable the company to create the first needle-free, room-temperature stable COVID-19 vaccine patch for clinical studies that are expected to begin in the coming months. HexaPro would be distributed into patients through Vaxxas’ proprietary high-density microarray patch (HD-MAP), a non-invasive vaccination platform designed for response to pandemic threats to public health . . .